Immuno-hyperthermia effected by antibody-conjugated nanoparticles selectively targets and eradicates individual cancer cells

Cell Cycle. 2021 Jul;20(13):1221-1230. doi: 10.1080/15384101.2021.1915604. Epub 2021 Jun 19.

Abstract

Hyperthermia has been used for cancer therapy for a long period of time, but has shown limited clinical efficacy. Induction-heating hyperthermia using the combination of magnetic nanoparticles (MNPs) and an alternating magnetic field (AMF), termed magnetic hyperthermia (MHT), has previously shown efficacy in an orthotopic mouse model of disseminated gastric cancer. In the present study, superparamagnetic iron oxide nanoparticles (SPIONs), a type of MNP, were conjugated with an anti-HER2 antibody, trastuzumab and termed anti-HER2-antibody-linked SPION nanoparticles (anti-HER2 SPIONs). Anti-HER2 SPIONs selectively targeted HER2-expressing cancer cells co-cultured along with normal fibroblasts and HER2-negative cancer cells and caused apoptosis only in the HER2-expressing individual cancer cells. The results of the present study show proof-of-concept of a novel hyperthermia technology, immuno-MHT for selective cancer therapy, that targets individual cancer cells.Abbreviations: AMF: alternating magnetic field; DDW: double distilled water; DMEM: Dulbecco's Modified Eagle's; Medium; f: frequency; FBS: fetal bovine serum; FITC: Fluorescein isothiocyanate; GFP: green fluorescent protein; H: amplitude; Hsp: heat shock protein; MHT: magnetic hyperthermia; MNPs: magnetic nanoparticles; PI: propidium iodide; RFP: red fluorescent protein; SPION: superparamagnetic iron oxide (Fe3O4) nanoparticle.

Keywords: Hyperthermia; cancer cells; immuno targeting; magnetic nanoparticles; selective eradication.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / chemistry
  • Antineoplastic Agents, Immunological / pharmacology*
  • Apoptosis / drug effects
  • Cell Proliferation / drug effects
  • Coculture Techniques
  • Drug Carriers*
  • Drug Compounding
  • HCT116 Cells
  • Humans
  • Hyperthermia, Induced*
  • Immunotherapy*
  • Kinetics
  • Magnetic Field Therapy*
  • Magnetic Fields
  • Magnetic Iron Oxide Nanoparticles*
  • Neoplasms / immunology
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Proof of Concept Study
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / metabolism

Substances

  • Antineoplastic Agents, Immunological
  • Drug Carriers
  • ERBB2 protein, human
  • Receptor, ErbB-2

Grants and funding

This work was supported by the Japan Society for the Promotion of Science [JP15K09959]; Japan Society for the Promotion of Science [JP19K07730].